Current Docket No. NC10001

 $\frac{Remarks}{\text{In the Communication dated 10 August 2006, restriction to one of the Groups below was required.}}$

Group I, claims 36-47 and 54-58 drawn to products;

Group II. claims 48-51 drawn to method of use:

Group III, claims 52 and 53 drawn to a process of preparing products

In response the Applicants elect for substantive examination Group I, listed for claims 36-47 and 54-58. The Applicants reserve the right to traverse when the restriction is made final and after the scope of the elected Group has been determined.

In addition, a species selection was required. In response, the Applicants, elect as a species, the compound disclosed by Example 32.

In the Office Action, the Applicants were invited to review the claims and set forth a group of compounds for examination, which are similar within the scope of the inventive concept and reduction to practice. (Office Action, page 4.) This the Applicants decline to do. However, it should be noted that claim 36 has been replaced by new claim 59, which includes amendments—in addition to those amendments which were presented in the preliminary amendment. For example, the ring formerly labeled as Q has been replaced with tetrahydropyran; the alkylene linker between the (former) double bond and Q has been amended to be but a single methylene group; the former double/single bond has been replaced with only a single bond; R¹, R², R⁵, and R⁶ have been removed (leaving hydrogens at these positions); and R⁸ has been amended to be either a cyclopropyl or cyclobutyl group. Therefore, it is believed that the claims as currently amended are sufficiently narrow in scope to permit the ready examination of the entire claimed scope without any undue burden.

Applicants reserve the right to file one or more continuing applications.

Additionally, the Applicants reserve their right to request rejoinder of the method claims under MPEP \$821.04 upon indication of allowable subject matter.

Please change the Attorney Docket Number to X-17599.

The Applicants request timely examination of the elected invention. The Examiner is

Current Docket No. NC10001

invited to contact the undersigned attorney by telephone if there are any questions about this submission or other issues that may be resolved in that fashion.

Respectfully submitted,

/James B. Myers/ James B. Myers Attorney for Applicants Registration No. 42,021 Phone: 317-276-0755

Eli Lilly and Company Patent Division P.O. Box 6288 Indianapolis, Indiana 46206-6288

8 February 2007